抗疹治疗可以降低痴呆症风险:系统性审查和元分析
Syuan-Ting Chang1, Hon-Yen Wu1,2,3,4, Yen-Ling Chiu4,5,6
1School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Journal of Alzheimer's disease : JAD
|December 30, 2025
概括
抗疹药物显示出对痴呆的保护作用,特别是在严重的阿尔法疹病毒感染中. 这一发现表明通过抗病毒治疗来管理痴呆风险的潜在好处.
科学领域:
- 神经科学是一个神经科学.
- 病毒学 病毒学
- 药理学 药理学是指药理学的学科.
背景情况:
- 人类疹病毒 (HHV) 感染,包括简单疹病毒 (HSV) 和疹病毒 (VZV),与痴呆症风险增加有关.
- 抗疹药物对痴呆症的保护作用仍然不完全理解.
研究的目的:
- 系统地审查和元分析关于抗疹药物和痴呆风险之间的关联的观察性研究.
- 在HSV或VZV感染的背景下,专注于痴呆风险.
主要方法:
- 按照PRISMA指南进行系统审查和元分析.
- 包括公布至2024年12月的队列或嵌套病例控制研究.
- 使用随机效应模型分析聚合的调整危险比率 (aHR) 和95%置信区间 (CI).
主要成果:
- 分析了14项超过1000万参与者的队列研究.
- 在各种比较中,使用抗疹药物与痴呆症风险降低有关.
- 感染严重程度是一个显著的修饰因素,解释了大量的异质性 (p < 0.0001).
结论:
- 使用抗疹药物显示出对痴呆的显著保护作用.
- 这种保护作用在患有严重阿尔法疹病毒感染的个体中尤为明显.
相关概念视频
Alzheimer's Disease: Treatment
736
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
736
Dementia
480
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
480
Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Atherosclerosis III: Management
290
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
290
Parkinson's Disease: Treatment
931
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
931
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
496
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
496


